Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Enthusiasm For US Biosimilars Wanes For Some, But Not Others

Aug 15 2018

• By Jessica Merrill

Related Content

Humira Biosimilar Settlement Could Be Model For Other Disputes

Sep 29 2017

Pfizer On Reorganizing, M&A And Investing In Internal R&D

Aug 01 2018

Teva Braces For A Bigger Hit As Price Competition Intensifies For Copaxone

Aug 02 2018

Mylan To Explore Strategic Options, Claiming Investors Have Failed To Appreciate The Value

Aug 08 2018

Legality Of J&J's Remicade Contracting Depends On Share Of Biosimilar Market Foreclosed, Court Rules

Aug 12 2018

Interchangeability Won’t Solve US Biosimilar Market’s Woes, FDA’s Gottlieb Says

Jul 19 2018

Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates

Oct 06 2016

FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market

Mar 08 2018

Mylan's Fulphila Sets Up The US Market For The Next Biosimilar Showdown

Jul 12 2018

Payers Like Biosimilars, But Rebates Remain The Bottom Line (For Now)

Nov 29 2017

Related Companies

Novartis AG

Amgen, Inc.

Viatris Inc.

Teva Pharmaceutical Industries Ltd.

Pfizer Inc.

Johnson & Johnson

Novartis AG

Celltrion, Inc.

AbbVie Inc.

Additional Topics

Biosimilars Commercial Launches BioPharmaceutical

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window